NASDAQ:CORT Corcept Therapeutics (CORT) Stock Price, News & Analysis → This Weight Loss Company Can't Make Enough Product (From Behind the Markets) (Ad) Free CORT Stock Alerts $28.59 -0.38 (-1.31%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$28.04▼$29.8350-Day Range$22.21▼$34.4852-Week Range$20.84▼$35.22Volume1.59 million shsAverage Volume1.40 million shsMarket Capitalization$2.98 billionP/E Ratio26.97Dividend YieldN/APrice Target$44.30 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Corcept Therapeutics alerts: Email Address Corcept Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside54.9% Upside$44.30 Price TargetShort InterestBearish21.49% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.84Based on 6 Articles This WeekInsider TradingSelling Shares$3.71 M Sold Last QuarterProj. Earnings Growth56.84%From $0.95 to $1.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.86 out of 5 starsMedical Sector26th out of 913 stocksPharmaceutical Preparations Industry9th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingCorcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorcept Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Corcept Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.49% of the float of Corcept Therapeutics has been sold short.Short Interest Ratio / Days to CoverCorcept Therapeutics has a short interest ratio ("days to cover") of 17.9, which indicates bearish sentiment.Change versus previous monthShort interest in Corcept Therapeutics has recently decreased by 2.58%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorcept Therapeutics has received a 70.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Corcept Therapeutics is -0.75. Previous Next 3.2 News and Social Media Coverage News SentimentCorcept Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Corcept Therapeutics this week, compared to 5 articles on an average week.Search Interest13 people have searched for CORT on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.MarketBeat Follows6 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,710,877.00 in company stock.Percentage Held by Insiders20.50% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corcept Therapeutics' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Corcept Therapeutics are expected to grow by 56.84% in the coming year, from $0.95 to $1.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 26.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 26.97, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 160.04.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 5.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corcept Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> About Corcept Therapeutics Stock (NASDAQ:CORT)Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Read More CORT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CORT Stock News HeadlinesJune 6, 2024 | insidertrades.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 SharesJune 6, 2024 | insidertrades.comInsider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 5,000 Shares of StockMay 31, 2024 | insidertrades.comInsider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 11,000 Shares of StockJune 17 at 12:24 PM | americanbankingnews.comTruist Financial Reiterates "Buy" Rating for Corcept Therapeutics (NASDAQ:CORT)June 16 at 2:48 AM | americanbankingnews.comCorcept Therapeutics (NASDAQ:CORT) Stock Price Down 8.1%June 11, 2024 | seekingalpha.comCorcept Therapeutics Stock Merits AccumulationJune 6, 2024 | stocknews.com3 Biotech Stocks for Investing in the FutureJune 3, 2024 | globenewswire.comCorcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome)May 28, 2024 | marketwatch.comCorcept Therapeutics Shares Rise 9% After Relacorilant Trial Meets Primary EndpointMay 28, 2024 | msn.comWhy Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday?May 28, 2024 | finance.yahoo.comCorcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)May 22, 2024 | benzinga.comLEONARD BAKER JR Makes A Tactical Move: Adds Corcept Therapeutics Stock Options To PortfolioMay 13, 2024 | finance.yahoo.com3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%May 3, 2024 | finance.yahoo.comCorcept Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 2, 2024 | gurufocus.comQ1 2024 Corcept Therapeutics Inc Earnings Call TranscriptMay 1, 2024 | investorplace.comCORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | sfgate.comCorcept: Q1 Earnings SnapshotMay 1, 2024 | finance.yahoo.comCorcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024May 1, 2024 | globenewswire.comCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate UpdateApril 29, 2024 | finance.yahoo.comCorcept Completes Enrollment in Phase 4 CATALYST TrialApril 24, 2024 | globenewswire.comCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallApril 23, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Market Potential: Buy Rating for Corcept’s RelacorilantApril 22, 2024 | msn.comMid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This QuarterApril 22, 2024 | msn.comCorcept falls after phase 3 results on Cushing's candidate doesn't include some dataApril 22, 2024 | finance.yahoo.comCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s SyndromeSee More Headlines Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/17/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CORT CUSIP21835210 CIK1088856 Webwww.corcept.com Phone(650) 327-3270Fax650-327-3218Employees352Year Founded1998Price Target and Rating Average Stock Price Target$44.30 High Stock Price Target$65.00 Low Stock Price Target$31.00 Potential Upside/Downside+54.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.06 Trailing P/E Ratio26.97 Forward P/E Ratio30.09 P/E GrowthN/ANet Income$106.14 million Net Margins22.38% Pretax Margin26.95% Return on Equity24.19% Return on Assets19.56% Debt Debt-to-Equity RatioN/A Current Ratio5.18 Quick Ratio5.10 Sales & Book Value Annual Sales$482.38 million Price / Sales6.17 Cash Flow$0.95 per share Price / Cash Flow30.25 Book Value$4.92 per share Price / Book5.81Miscellaneous Outstanding Shares104,110,000Free Float82,767,000Market Cap$2.98 billion OptionableOptionable Beta0.46 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Joseph K. Belanoff M.D. (Age 67)Co-Founder, President, CEO & Director Comp: $2.43MMr. Atabak Mokari (Age 47)CFO & Treasurer Comp: $863.03kMr. Sean Maduck (Age 47)President of Endocrinology Comp: $1.05MDr. William Guyer Pharm.D. (Age 56)Chief Development Officer Comp: $1.03MMr. Gary Charles Robb (Age 61)Chief Business Officer & Secretary Comp: $1.08MMr. Joseph Douglas Lyon (Age 46)Chief Accounting & Technology Officer Dr. Hazel Hunt Ph.D. (Age 64)Chief Scientific Officer Comp: $895.16kMs. Amy FloodChief Human Resources & Communications OfficerMs. Monica Tellado (Age 51)President of Emerging Markets Mr. Roberto W. VieiraPresident of OncologyMore ExecutivesKey CompetitorsAxsome TherapeuticsNASDAQ:AXSMRa PharmaceuticalsNASDAQ:RARXGlobal Blood TherapeuticsNASDAQ:GBTHarmony BiosciencesNASDAQ:HRMYTaro Pharmaceutical IndustriesNYSE:TAROView All CompetitorsInsiders & InstitutionsJoseph Douglas LyonSold 5,000 sharesTotal: $150,900.00 ($30.18/share)Daniel N. Swisher, Jr.Sold 2,200 sharesTotal: $66,462.00 ($30.21/share)Gary Charles RobbSold 11,000 sharesTotal: $334,290.00 ($30.39/share)Cetera Advisors LLCBought 13,502 shares on 5/24/2024Ownership: 0.013%Burney Co.Bought 12,402 shares on 5/22/2024Ownership: 0.415%View All Insider TransactionsView All Institutional Transactions CORT Stock Analysis - Frequently Asked Questions Should I buy or sell Corcept Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CORT shares. View CORT analyst ratings or view top-rated stocks. What is Corcept Therapeutics' stock price target for 2024? 4 Wall Street analysts have issued 1 year price objectives for Corcept Therapeutics' stock. Their CORT share price targets range from $31.00 to $65.00. On average, they anticipate the company's stock price to reach $44.30 in the next year. This suggests a possible upside of 54.9% from the stock's current price. View analysts price targets for CORT or view top-rated stocks among Wall Street analysts. How have CORT shares performed in 2024? Corcept Therapeutics' stock was trading at $32.48 at the start of the year. Since then, CORT stock has decreased by 12.0% and is now trading at $28.59. View the best growth stocks for 2024 here. When is Corcept Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our CORT earnings forecast. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) released its earnings results on Wednesday, May, 1st. The biotechnology company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.04. The biotechnology company had revenue of $146.80 million for the quarter, compared to analysts' expectations of $141.19 million. Corcept Therapeutics had a trailing twelve-month return on equity of 24.19% and a net margin of 22.38%. The firm's quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS. What ETFs hold Corcept Therapeutics' stock? ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Pharmaceuticals ETF (PJP), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO) and ETC 6 Meridian Small Cap Equity ETF (SIXS). What guidance has Corcept Therapeutics issued on next quarter's earnings? Corcept Therapeutics issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $610.6 million. What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO? 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI). Who are Corcept Therapeutics' major shareholders? Corcept Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.19%), Norden Group LLC (1.92%), Ikarian Capital LLC (0.00%), Jupiter Asset Management Ltd. (0.72%), Jacobs Levy Equity Management Inc. (0.70%) and Kynam Capital Management LP (0.00%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff, Sean Maduck and William Guyer. View institutional ownership trends. How do I buy shares of Corcept Therapeutics? Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CORT) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.